AMEISHA SCOTT: Open Payments
NPI 1851609028 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,335 in 58 payments from 11 companies in 2025. Trend: 2023 $878 · 2024 $1,179 · 2025 $1,335
Food & beverage: $1,114Education: $221
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 11 | $403 |
| Neurocrine BioSciences, Inc. | 13 | $254 |
| Otsuka America Pharmaceutical, Inc. | 11 | $188 |
| Alkermes, Inc. | 8 | $180 |
| Lundbeck LLC | 3 | $68 |
| Axsome Therapeutics, Inc. | 3 | $56 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $49 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
| ABBVIE INC. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
Products named: INGREZZA, ARISTADA, REXULTI, AUSTEDO XR, UZEDY, ABILIFY ASIMTUFII, Auvelity, ABILIFY MAINTENA.
Industry payments across TX — which companies pay providers there.
